[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 18 of about 18
2. Ahn MJ, Park YW, Han D, Choi JH, Shin SJ, Yoon BC, Choi HS, Lee YY, Jung TJ, Choi IY, Park MH, Kim IS: A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum. Korean J Intern Med; 2000 Dec;15(3):245-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum.
  • Primary intestinal T-cell lymphoma is a rare disease entity, which is approximately 10% to 25% of intestinal lymphomas, and most of the lymphomas occur in the small intestine.
  • Gastroscopic examination showed diffuse erythematous lesions on the esophagus and small gastric ulcerations on the antrum of the stomach, and colonoscopic examination also showed multiple punched-out ulcerations and erosions on the entire colon, including the sigmoid colon to the terminal ileum.
  • Diffuse infiltration of CD 3 positive lymphoma cells was found on biopsy.
  • The patient was diagnosed as primary intestinal T-cell lymphoma with diffuse involvement of the entire gastrointestinal tracts from the esophagus to the rectum.
  • Although the patient received systemic combination chemotherapy and achieved partial response initially, the lymphoma relapsed repeatedly.
  • [MeSH-major] Esophageal Neoplasms / therapy. Gastrointestinal Neoplasms / therapy. Lymphoma, T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11242815.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC4531775
  •  go-up   go-down


3. Posey JA 3rd, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW: Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res; 2005 Nov 1;11(21):7866-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Eligible patients had advanced solid tumors that failed to respond to standard therapy or for which no standard therapy was available, including also the following criteria: measurable disease, Eastern Cooperative Oncology Group performance status of < or =2, and acceptable organ function.
  • The primary end point was to determine the maximal tolerated dose.
  • Pharmacodynamic analysis correlated drug effects with pegamotecan dose and pharmacokinetic variables.
  • Other grade 3 and 4 toxicities were anemia, thrombocytopenia, fatigue, prolonged partial thromboplastin time, hemorrhagic cystitis, dysuria, and urinary frequency.
  • Unconfirmed partial responses were observed in two patients, one with metastatic small bowel adenocarcinoma and the other with metastatic esophageal cancer.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Camptothecin / administration & dosage. Camptothecin / pharmacokinetics. Lymphoma / drug therapy. Neoplasms / drug therapy. Polyethylene Glycols / administration & dosage
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Area Under Curve. Dose-Response Relationship, Drug. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278410.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR00032
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 30IQX730WE / Polyethylene Glycols; 581079-18-7 / pegamotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


Advertisement
4. Hosoya Y, Yokoyama T, Arai W, Hyodo M, Nishino H, Sugawara Y, Yasuda Y, Nagai H: Tracheoesophageal fistula secondary to chemotherapy for malignant B-cell lymphoma of the thyroid: successful surgical treatment with jejunal interposition and mesenteric patch. Dis Esophagus; 2004;17(3):266-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracheoesophageal fistula secondary to chemotherapy for malignant B-cell lymphoma of the thyroid: successful surgical treatment with jejunal interposition and mesenteric patch.
  • We report a case of tracheoesophageal fistula (TEF) secondary to chemotherapy for primary thyroid lymphoma.
  • A 65-year-old man with a short history of a rapidly enlarging neck mass was diagnosed as having thyroid lymphoma of diffuse, large B-cell type.
  • The TEF occurred during the first course of chemotherapy including cyclophosphamide, doxorubicin, vincristine and prednisolone.
  • After placing a feeding gastrostomy without oral intake, eight cycles of chemotherapy were completed and complete remission was achieved.
  • Although the cervical mass disappeared, TEF and esophageal stenosis persisted.
  • Total thyroidectomy and resection of the stenotic cervical esophagus were carried out followed by interposition of the revascularized jejunum and its mesenteric patch to cover the TEF.
  • This seems to be the first report of a TEF caused by chemotherapy for primary thyroid B-cell lymphoma.
  • A variety of treatments for TEF including simple closure, tracheal resection, colonic bypass and muscle flap have been reported with low success rates.
  • Our procedure using a jejunal mesenteric patch seems to be unique and may be a new treatment strategy for TEF.

  • Genetic Alliance. consumer health - Tracheoesophageal fistula.
  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15361103.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


5. Yukiiri K, Mizushige K, Ueda T, Kohno M: Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report. Angiology; 2001 Aug;52(8):563-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report.
  • A 76-year-old man was found to have esophageal squamous cell carcinoma and had been treated with radiational therapy and chemotherapy.
  • An echocardiographic examination revealed a mass lesion in the pericardium with pericardial effusion behind the left ventricular posterior wall, which was near the site of the original esophageal cancer.
  • No findings indicated a recurrence of the esophageal cancer; cytologic studies showed malignant lymphoma cells of B-cell origin.
  • A second primary cancer of some organs including blood cells might be induced by the carcinogenic effects of ionizing radiation or chemotherapeutic agents.
  • This is the first case of second primary cardiac B-cell lymphoma after combination therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy. Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Cisplatin / administration & dosage. Coronary Angiography. Echocardiography, Transesophageal. Esophagoscopy. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Pericardial Effusion / pathology. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11512697.001).
  • [ISSN] 0003-3197
  • [Journal-full-title] Angiology
  • [ISO-abbreviation] Angiology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


6. Ohtsu A: The latest advances in chemotherapy for gastrointestinal cancers. Int J Clin Oncol; 2003 Aug;8(4):234-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The latest advances in chemotherapy for gastrointestinal cancers.
  • During the past decade, there has been much progress in various nonsurgical treatments for gastrointestinal malignancies.
  • Endoscopic mucosal resection (EMR) has been widely used as a standard treatment for early gastrointestinal cancers in Japan.
  • For esophageal cancer, definitive chemoradiotherapy with or without EMR has shown the possibility of results comparable with those of surgery in stage I-III disease and is being evaluated in Japan Clinical Oncology Group (JCOG) studies.
  • Definitive chemoradiotherapy with curative intent for locally advanced (T4/M1a) diseases has had a 5-year survival of 17%.
  • In gastric cancers, although no standard regimen has been established yet, recently developed new agents have achieved higher response rates than before.
  • There has been obvious progress in chemotherapy for colorectal cancer.
  • Newly developed agents such as irinotecan and oxaliplatin have provided significant survival prolongation for metastatic colorectal cancer in randomized trials.
  • In other gastrointestinal malignancies, nonsurgical treatments, including eradication of Helicobacter pylori, chemotherapy, and radiotherapy for primary gastric lymphoma are being evaluated in prospective studies.
  • A new molecular targeting agent, imatinib, has provided significant impact in the treatment of gastrointestinal stromal tumor.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Neoplasms / drug therapy
  • [MeSH-minor] Clinical Trials as Topic. Helicobacter Infections / drug therapy. Helicobacter pylori. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12955579.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 16
  •  go-up   go-down


7. Park S, Jeen YT, Kwon YD, Keum B, Seo YS, Kim YS, Chun HJ, Um SH, Kim CD, Ryu HS: Successfully cured primary esophageal lymphoma in a patient with acquired immune deficiency syndrome (AIDS). Endoscopy; 2009;41 Suppl 2:E148-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successfully cured primary esophageal lymphoma in a patient with acquired immune deficiency syndrome (AIDS).
  • [MeSH-major] Esophageal Neoplasms / drug therapy. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Esophagoscopy. Humans. Male

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544273.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Sumi M, Takaku T, Iguchi T, Ishii Y, Katagiri T, Tauchi T, Serizawa H, Mukai K, Ohyashiki K: [Primary diffuse large B-cell lymphoma of the esophagus]. Rinsho Ketsueki; 2004 Sep;45(9):1067-9
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary diffuse large B-cell lymphoma of the esophagus].
  • A 64-year-old man with primary esophageal lymphoma suffered from dysphagia.
  • An upper gastrointestinal examination revealed a partly ulcerated submucosal tumor in the upper portion of the esophagus.
  • Histopathological and immunohistological examination of endoscopic biopsy specimens showed diffuse large B-cell lymphoma of the immunoblastic type.
  • Improvement of the dysphagia and esophageal findings were noted after chemotherapy and radiotherapy.
  • A review of the literature indicated that primary esophageal lymphomas account for less than 1% of all gastrointestinal lymphomas, and less than 0.1% of all malignant lymphomas.
  • Because of the rarity of primary esophageal lymphoma, its clinical and biological characteristics are not currently well known.
  • It is important to accumulate information on, and to further investigate patients with, primary esophageal lymphoma.
  • [MeSH-major] Esophageal Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510839.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Wei SH, Sheen JM, Huang CB, Hsiao CC: Primary spinal epidural non-Hodgkin's lymphoma in a child. Chang Gung Med J; 2001 Dec;24(12):820-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary spinal epidural non-Hodgkin's lymphoma in a child.
  • Non-Hodgkin's lymphoma usually involves the central nervous system by metastatic disease.
  • Primary spinal epidural non-Hodgkin's lymphoma (PSENL) is a relatively rare cause of spinal cord compression.
  • The proper treatment modalities are controversial in adults with PSENL.
  • Radiotherapy is the main strategy after surgery; the role of chemotherapy is uncertain.
  • Therapeutic experience in childhood PSENL is extremely limited.
  • Small non-cleaved cell non-Hodgkin's lymphoma of the epidural space was proven after subtotal tumor removal.
  • Other investigations including computed tomography of the chest and abdomen, bone scan, gallium scan, bone marrow aspiration, and cerebrospinal fluid study were all negative for occult disease.
  • The patient received combined therapy with irradiation and chemotherapy after surgery.
  • Esophageal stricture resulting from radiotherapy developed during treatment and colon interposition was performed.
  • [MeSH-major] Epidural Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Child. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11858400.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


10. Tagami K, Tanda S, Tokumura H, Yamaguchi M: [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2891-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of triple malignant tumors consisting of esophagus, stomach and malignant lymphoma with a histopathological feature of collision between gastric cancer and malignant lymphoma--a case report].
  • We report a rare case of a collision between a gastric cancer and a malignant lymphoma with a wide systemic metastasis, combined with esophagus cancer, stomach cancer and malignant lymphoma.
  • He was diagnosed with malignant diffuse large B cell lymphoma by immunostaining from the extirpated right testis.
  • He received six cycles of R-CHOP therapy.
  • Thereafter, we performed MTX-HOPE therapy as a salvage therapy for four cycles.
  • During this chemotherapy, he felt epigastralgia; esophagus cancer (squamous cell carcinoma) and stomach cancer (highly-differentiated adenocarcinoma) were found by upper endoscopy.
  • However, the gastrointestinal cancer was inoperable, since the malignant lymphoma was progressive.
  • His general status had been exacerbated, and he died about one year after he was diagnosed with malignant lymphoma.
  • Pathological examination revealed that the adenocarcinoma had partly collided with the malignant lymphoma.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Esophageal Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160264.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Koharazawa H, Yamaji S, Takasaki H, Takabayashi M, Fujimaki K, Taguchi J, Kanamori H, Ishigatsubo Y: [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma]. Rinsho Ketsueki; 2005 Jul;46(7):496-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Triple secondary malignancy of gingiva, palate and esophagus after an allogeneic bone marrow transplantation for cutaneous T-cell lymphoma].
  • A 31-year-old man was diagnosed as having cutaneous T-cell lymphoma in January 1994.
  • He received an allogeneic bone marrow transplantation (BMT) from an HLA-matched sibling donor in May 1995, because of refractoriness to chemotherapy.
  • The patient had been treated with immunosuppressants including prednisolone and cyclosporin A for chronic graft-versus-host disease (GVHD) of the extensive type following acute GVHD.
  • Five years after the BMT, he developed moderately differentiated squamous cell carcinoma (SCC) on the mandibular gingival mucosa and underwent surgical resection.
  • Furthermore, 6 years after the BMT well differentiated SCC developed on his palate and was resected.
  • Concurrently, he was diagnosed as having esophageal cancer (poorly differentiated SCC) and underwent a subtotal esophagotomy.
  • One year later he had a recurrence of the esophageal cancer with dysphagia and was treated with radiation and chemotherapy.
  • He remains free of triple cancer and lymphoma.
  • [MeSH-major] Bone Marrow Transplantation. Carcinoma, Squamous Cell. Esophageal Neoplasms. Gingival Neoplasms. Lymphoma, T-Cell, Cutaneous / therapy. Neoplasms, Second Primary. Palatal Neoplasms. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Graft vs Host Disease / complications. Humans. Immunosuppressive Agents / adverse effects. Male. Transplantation, Homologous. Treatment Outcome. Whole-Body Irradiation / adverse effects


13. Ng E, Ilsen PF: Orbital metastases. Optometry; 2010 Dec;81(12):647-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • If suspecting an orbital metastasis, neuroimaging is important, as well as a referral to the patient's primary care provider, oncologist, and ophthalmologist.
  • Magnetic resonance imaging of his orbits and an orbital biopsy found metastatic esophageal adenocarcinoma.
  • Radiotherapy and chemotherapy were initiated, but the patient died shortly afterward.
  • An area of the retina appeared elevated; ophthalmic B-scan and computed tomography of the orbits confirmed the presence of a mass, determined to be metastatic lung carcinoma to the right orbit.
  • A course of radiotherapy was initiated, but the patient died 3 days after completing therapy.
  • The last case was a 77-year-old white man with a history of metastasis to the left orbit from non-Hodgkin's lymphoma.
  • However, a computed tomography scan showed a new meningioma in the same orbit, and treatment was started.
  • Prognosis can be poor, and thus treatment is sometimes palliative in nature, intending to slow the progression of the disease instead of providing a cure.
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / therapy. Aged. Blepharoptosis / etiology. Diplopia / etiology. Esophageal Neoplasms / pathology. Exophthalmos / etiology. Humans. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Magnetic Resonance Imaging. Male. Meningioma / pathology. Middle Aged. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Optometric Association. All rights reserved.
  • (PMID = 21111373.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Jacobi D, de Muret A, Arbeille B, Perarnau JM: Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension secondary to non-cirrhotic perisinusoidal hepatic fibrosis. Eur J Gastroenterol Hepatol; 2006 May;18(5):549-51
MedlinePlus Health Information. consumer health - Cirrhosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transjugular intrahepatic portosystemic shunt for the treatment of portal hypertension secondary to non-cirrhotic perisinusoidal hepatic fibrosis.
  • Exposure to chemicals, auto-immunity, thrombophilia and/or infections are suspected primary agents.
  • Here, we present the case of a patient who developed severe portal hypertension with histological features suggesting a non-cirrhotic perisinusoidal hepatic fibrosis.
  • Liver cirrhosis or portal vein thrombosis were absent as attested by laboratory tests, duplex sonography, computed tomography scan and histological examination of a liver biopsy specimen.
  • This was most probably secondary to a combined chemotherapy received 4 years earlier for non-Hodgkin large-cell lymphoma.
  • This case illustrates the use of TIPS in the treatment of portal hypertension secondary to non-cirrhotic perisinusoidal fibrosis.
  • [MeSH-major] Esophageal and Gastric Varices / surgery. Liver Cirrhosis / surgery. Portasystemic Shunt, Transjugular Intrahepatic / methods

  • Genetic Alliance. consumer health - Hepatic fibrosis.
  • Genetic Alliance. consumer health - Portal hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607154.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Conti S, Masocco M, Pezzotti P, Toccaceli V, Vichi M, Boros S, Urciuoli R, Valdarchi C, Rezza G: Differential impact of combined antiretroviral therapy on the survival of italian patients with specific AIDS-defining illnesses. J Acquir Immune Defic Syndr; 2000 Dec 15;25(5):451-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential impact of combined antiretroviral therapy on the survival of italian patients with specific AIDS-defining illnesses.
  • BACKGROUND: A decrease in HIV-related mortality and morbidity has been observed since 1996 in most developed countries as a consequence of the extensive use of combined antiretroviral therapies.
  • The purpose of this study was to investigate whether combined antiretroviral therapies had a differential impact on the survival of patients with different AIDS-defining illnesses (ADIs).
  • Significantly decreased RHs for some ADIs were observed as early as 1996 (i.e., esophageal candidiasis, Pneumocystis carinii pneumonia, brain toxoplasmosis, HIV-wasting syndrome, and pulmonary tuberculosis).
  • Conversely, primary lymphoma of the brain and Burkitt's lymphoma showed a low and not statistically significant decrease; these were the ADIs with the worst outcome.
  • CONCLUSIONS: After 1995, there was a rather uniform increase in the survival of PWAs diagnosed with most specific ADIs but not for patients affected by primary brain lymphoma and Burkitt's lymphoma.
  • [MeSH-major] AIDS-Related Opportunistic Infections / mortality. Acquired Immunodeficiency Syndrome / drug therapy. Acquired Immunodeficiency Syndrome / mortality. Anti-HIV Agents / therapeutic use. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adolescent. Adult. Drug Therapy, Combination. Female. Humans. Italy / epidemiology. Male. Middle Aged. Proportional Hazards Models. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11141245.001).
  • [ISSN] 1525-4135
  • [Journal-full-title] Journal of acquired immune deficiency syndromes (1999)
  • [ISO-abbreviation] J. Acquir. Immune Defic. Syndr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


16. Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, Kuwabara M, Yagyu Y, Kumano S, Imaoka I, Tsuchiya N, Ashikaga R, Hosono M, Murakami T: Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med; 2009 Jun;23(4):349-54
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
  • OBJECTIVE: To investigate whether integrated fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can differentiate benign from adrenal malignant lesions on the basis of maximum standardized uptake value (SUV(max)), tumor/liver (T/L) SUV(max) ratio, and CT attenuation value (Hounsfield Units;.
  • METHODS: We studied 30 patients with 35 adrenal lesions (16 adrenal benign lesions, size 16 +/- 5 mm, in 15 patients; and 19 adrenal malignant lesions, 24 +/- 12 mm, in 15 patients) who had confirmed primary malignancies (lung cancer in 23 patients, lymphoma in 2, esophageal cancer in 2, hypopharyngeal cancer in 1, prostate cancer in 1, and 1 patient in whom lesions were detected at cancer screening).
  • Diagnosis of adrenal malignant lesions was based on interval growth or reduction after chemotherapy.
  • In further analysis, 1.8 was employed as the threshold for the T/L SUV(max) ratio.
  • The T/L SUV(max) ratio was 1.0 +/- 0.2 for adrenal benign lesions and 4.5 +/- 3.0 for adrenal malignant lesions.
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Liver / metabolism. Middle Aged. Positron-Emission Tomography. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19340526.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Treiber G, Malfertheiner P: [Helicobacter pylori--2002]. Praxis (Bern 1994); 2002 May 1;91(18):773-8
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment recommendations for H. pylori infection are peptic ulcer disease, MALT lymphoma, atrophic gastritis and following gastric cancer resection as well as first degree relatives of gastric cancer patients.
  • Advisable situations are functional dyspepsia, before introduction of NSAID's or intended long-term proton-pump inhibitor treatment.
  • It is thought that eradication therapy is not associated with gastro-esophageal reflux disease and does not enhance NSAID induced peptic ulcer healing.
  • Therapy should be given as a package which considers first and second line eradication therapies together; in uncomplicated duodenal ulcer patients, eradication therapy does not need to be followed by further antisecretory treatment.
  • First line therapy should be with triple therapy using a proton pump inhibitor (PPI), combined with clarithromycin and amoxycilline or metronidazole.
  • Second-line therapy should use a quadruple therapy with a PPI, bismuth, metronidazole and tetracycline.
  • Where bismuth is not available, second line therapy should be with a PPI triple therapy.
  • If second line quadruple therapy fails in primary care, patients should be referred to the specialist and handled on a case by case basis.
  • A 'test and treat' approach based on non-invasive testing can be offered to adult patients presenting in primary care with persistent dyspepsia under the age of 45 years (the age cut-off may vary locally), having excluded those with predominantly gastroesophageal reflux disease (GERD) symptoms, NSAID users, and patients with alarm symptoms.
  • [MeSH-major] Anti-Bacterial Agents. Anti-Ulcer Agents / therapeutic use. Drug Therapy, Combination / therapeutic use. Helicobacter Infections / drug therapy. Helicobacter pylori. Proton Pump Inhibitors. Stomach Diseases / drug therapy

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12071078.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Ulcer Agents; 0 / Proton Pump Inhibitors
  •  go-up   go-down


18. Williams G, Pazdur R, Temple R: Assessing tumor-related signs and symptoms to support cancer drug approval. J Biopharm Stat; 2004 Feb;14(1):5-21
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing tumor-related signs and symptoms to support cancer drug approval.
  • While prolongation of survival is an obvious end point for new cancer drug approval, the US Food and Drug Administration (FDA) has also utilized end points that evaluate patient symptoms.
  • In this article we discuss the end points, evidence, and analyses supporting cancer drug approvals based on evaluations of tumor-related signs and symptoms.
  • With advice from the Oncologic Drug Advisory Committee (ODAC) in the late 1970s and early 1980s, FDA determined that acceptable end points for cancer drug approval were survival or an improvement in the quality of a patient's life, e.g., an improvement in tumor-related symptoms.
  • This article summarizes 15 FDA cancer drug approvals based on patient symptom assessments and/or physical signs (thought to represent symptomatic improvement) as the primary evidence of effectiveness.
  • These include painful bone events (three cases), cosmetic improvement in Kaposi's sarcoma and cutaneous T-cell lymphoma (six cases), the consequences (decreased transfusions, etc.) of long-duration responses in leukemias and lymphomas (two cases), relief of pulmonary or esophageal obstruction (two cases), and one case each of symptom benefit in pancreatic cancer (also associated with survival benefit) and pulmonary symptom benefit in lung cancer.
  • An instructive example of an individual patient benefit end point is discussed, though it did not lead to a drug approval (the cisplatin-epinephrine gel application).
  • Improved trial designs and analysis plans may allow greater reliance on morbidity assessments to support future cancer drug approvals.
  • Drug sponsors are encouraged to include symptom assessments in cancer clinical trials and to perform further research to improve symptom-assessment methods.
  • The FDA routinely meets with sponsors at End of Phase 2 Meetings to discuss drug development plans and the design of phase 3 trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Approval / statistics & numerical data. Neoplasms / drug therapy. United States Food and Drug Administration / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15027497.001).
  • [ISSN] 1054-3406
  • [Journal-full-title] Journal of biopharmaceutical statistics
  • [ISO-abbreviation] J Biopharm Stat
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 15
  •  go-up   go-down






Advertisement